Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | CASP3 | P42574 | 2/20 | 0.44 |
| ▸ | FABP7 | O15540 | 2/20 | 0.43 |
| ▸ | FABP5 | Q01469 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29511484 | 1.00 | KMT2A (0.63) | KMT2ASMN1; SMN2LMNAEPHX2CASP3 | |
| SCHEMBL29409577 | 1.00 | KMT2A (0.63) | KMT2ASMN1; SMN2LMNAEPHX2CASP3 | |
| SCHEMBL31749859 | 1.00 | KMT2A (0.63) | KMT2ASMN1; SMN2LMNAEPHX2CASP3 | |
| SCHEMBL31355501 | 1.00 | KMT2A (0.63) | KMT2ASMN1; SMN2LMNAEPHX2CASP3 | |
| SCHEMBL178765 | 1.00 | KMT2A (0.63) | KMT2ASMN1; SMN2LMNAEPHX2CASP3 | |
| SCHEMBL4557019 | 1.00 | KMT2A (0.63) | KMT2ASMN1; SMN2LMNAEPHX2CASP3 | |
| SCHEMBL1593608 | 1.00 | KMT2A (0.63) | KMT2ASMN1; SMN2LMNAEPHX2CASP3 | |
| SCHEMBL4557247 | 1.00 | KMT2A (0.63) | KMT2ASMN1; SMN2LMNAEPHX2CASP3 | |
| SCHEMBL31309927 | 1.00 | KMT2A (0.63) | KMT2ASMN1; SMN2LMNAEPHX2CASP3 | |
| SCHEMBL29634951 | 1.00 | KMT2A (0.63) | KMT2ASMN1; SMN2LMNAEPHX2CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1509 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106749613-B | Synthetic method of somaglutide | 江苏诺泰澳赛诺生物制药股份有限公司 | 2020-08-18 | — | — | CN | claimed |
| US-20190352625-A1 | MUTANTS OF COCAINE ESTERASE | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2019-11-21 | — | — | US | claimed |
| US-10160960-B2 | Mutants of cocaine esterase | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2018-12-25 | — | — | US | claimed |
| US-20180057558-A1 | Synthesis of GLP-1 Peptides | NOVETIDE, LTD. (IL) | 2018-03-01 | — | — | US | claimed |
| EP-3221342-A1 | SYNTHESIS OF GLP-1 PEPTIDES | Novetide Ltd. (IL) | 2017-09-27 | — | — | EP | claimed |
| US-20160177277-A1 | MUTANTS OF COCAINE ESTERASE | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2016-06-23 | — | — | US | claimed |
| WO-2016046753-A1 | SYNTHESIS OF GLP-1 PEPTIDES | NOVETIDE, LTD. (IL) | 2016-03-31 | — | — | WO | claimed |
| EP-2111237-B1 | FIBRIN-BINDING PEPTIDES AND CONJUGATES THEREOF | BRACCO IMAGING SPA (IT) | 2015-03-18 | — | — | EP | claimed |
| WO-2015021187-A1 | MUTANTS OF COCAINE ESTERASE | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2015-02-12 | — | — | WO | claimed |
| US-20140134197-A1 | Mimotopic Peptides for the Diagnosis and Treatment of Multiple sclerosis | Calenoff, Emanuel (US) | 2014-05-15 | — | — | US | claimed |
| US-20080267988-A1 | Myelin specific IgE unencumbered by corresponding blocking antibodies as a causative factor in multiple sclerosis | ENTERON LIMITED PARTNERSHIP (US) | 2008-10-30 | — | — | US | claimed |
| WO-2008127642-A1 | MYELIN SPECIFIC IGE UNENCUMBERED BY CORRESPONDING BLOCKING ANTIBODIES AS A CAUSATIVE FACTOR IN MULTIPLE SCLEROSIS | ENTERON LIMITED PARTNERSHIP (US) | 2008-10-23 | — | — | WO | claimed |
| US-20260132182-A1 | CO-AGONISTS OF THE GLP-1 AND AMYLIN RECEPTORS | NOVO NORDISK AS (DK) | 2026-05-14 | — | — | US | disclosed |
| EP-4740955-A2 | NOVEL GLP-1 ANALOGUES | Sun Pharmaceutical Industries Limited (IN) | 2026-05-13 | — | — | EP | disclosed |
| US-20260125445-A1 | GLP-1 DERIVATIVES AND USES THEREOF | NOVO NORDISK AS (DK) | 2026-05-07 | — | — | US | disclosed |
| EP-4731257-A1 | CONJUGATES OF SAPONIN AND ANTISENSE OLIGONUCLEOTIDES FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | Sapreme Technologies B.V. (NL) | 2026-04-29 | — | — | EP | disclosed |
| WO-1999037670-A1 | SYNTHETIC POLYMERS AND METHODS, KITS OR COMPOSITIONS FOR MODULATING THE SOLUBILITY OF SAME | BOSTON PROBES, INC. (US) | 1999-07-29 | — | — | WO | disclosed |
| WO-1999022018-A2 | METHODS, KITS AND COMPOSITIONS PERTAINING TO PNA MOLECULAR BEACONS | BOSTON PROBES, INC. (US) | 1999-05-06 | — | — | WO | disclosed |
| WO-1999021881-A1 | METHODS, KITS AND COMPOSITIONS PERTAINING TO LINEAR BEACONS | BOSTON PROBES, INC. (US) | 1999-05-06 | — | — | WO | disclosed |
| WO-1998024933-A1 | METHODS, KITS AND COMPOSITIONS FOR SUPPRESSING THE BINDING OF DETECTABLE PROBES TO NON-TARGET SEQUENCES IN HYBRIDIZATION ASSAYS | BOSTON PROBES, INC. (US) | 1998-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180057558-A1 | Synthesis of GLP-1 Peptides | GLP1R, GIPR, IAPP | KMT2A 2774/4885SMN1; SMN2 4062/4885LMNA 3319/4885 |
| US-20260132182-A1 | CO-AGONISTS OF THE GLP-1 AND AMYLIN RECEPTORS | GLP1R, GCGR, GIPR | KMT2A 2360/4885SMN1; SMN2 3048/4885LMNA 3349/4885 |
| US-20260125445-A1 | GLP-1 DERIVATIVES AND USES THEREOF | GLP1R, GIPR, ARRB1 | KMT2A 2440/4885SMN1; SMN2 3963/4885LMNA 2760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.